University of Kentucky

UKnowledge
Graduate Center for Nutritional Sciences
Faculty Patents

Nutritional Sciences

12-17-2002

Method for Inhibition of Photocarcinogenesis or
Photoimmunosuppression Using Niacin
Elaine L. Jacobson
University of Kentucky

Helen L. Gensler

Follow this and additional works at: https://uknowledge.uky.edu/nutrisci_patents
Part of the Medical Pharmacology Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Jacobson, Elaine L. and Gensler, Helen L., "Method for Inhibition of Photocarcinogenesis or
Photoimmunosuppression Using Niacin" (2002). Graduate Center for Nutritional Sciences Faculty
Patents. 9.
https://uknowledge.uky.edu/nutrisci_patents/9

This Patent is brought to you for free and open access by the Nutritional Sciences at UKnowledge. It has been
accepted for inclusion in Graduate Center for Nutritional Sciences Faculty Patents by an authorized administrator
of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

US006495537B1

(12)

(54)

United States Patent

(10) Patent N0.:

Jacobson et al.

(45) Date of Patent:

METHOD FOR INHIBITION OF
PHOTOCARCINOGENESIS OR
JP

08301760
11/1996
OTHER PUBLICATIONS

(75) Inventors: Elaine L. Jacobson, Tucson, AZ (US);
Helen L' Gensler’ Tucson’ AZ (Us)

(73) Assigneez University of Kentucky Research
Notice:

Dec. 17, 2002

FOREIGN PATENT DOCUMENTS

PHOTOIMMUNOSUPPRESSION USING
NIACIN

(4)

US 6,495,537 B1

eltggghcancer Research’ VOL 50’ pp' 2470_2475’
Helen L. Gensler et al., Oral Niacin Prevents Photocarcino

gegesis and Photoimmunosuppression in Mice, Nutrition

Foundation, Lexington, KY (US)

an Cancer’ 34(1)’ 36_41 (1999),‘
_ _ _
Jacobson et al., “Chemoprevention by niacin in a mouse

Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U_S_C_ 154(k)) by 0 days

modelof uv—induced skin carcinogenesis” Proc. Annu Meet
Am Assoc Cancer Res; 37:1900 (1996) (meeting abstract).
Helen L. Gensler, Prevention of Photoimmunosuppression

and Photocarcinogenesis by Topical Nicotinamide, Nutrition
_

and Cancer, 29(2), 157—162 (1997).

(21) Appl' NO" 09/452’745
(22) Filed;
Dec, 1, 1999

E.L. Jacobson and M.K. Jacobson, A biomarker for the
assessment of niacin nutriture as a potential preventive
factor in carcinogenesis, Journal of Internal Medicine, 223:

(Under 37 CFR 1.47)

59_62 (1993)'
Database Dissertation Abstracts Online Modulation of car

Related US. Application Data

(60)

-

Provisional application No. 60/110,483, ?led on Dec. 1,
1998.

-

b

(13161505 irlngcgg;Ocess

-

-

t t

’1 59 N

y macm S a us’ V0 '

’

03_B

0'

’ p‘

'

(51)

Int. c1.7 ..................... .. A61K 31/33; A61K 31/455

* ‘med by exammer

(52)

US. Cl. ..................... .. 514/183; 514/844; 514/846;

Primary Examiner—larnes O. Wilson

424/59; 424/401
(58) Field Of Search ................. .. 424/59, 4:11i/giil/814863,
,

(56)

References Cited
U.S. PATENT DOCUMENTS
5,496,827 A

3/1996 Patrick

5,582,817 A

* 12/1996 Otsu et a1.

5,747,049 A *

5/1998 Tominaga

(74) Attorney, Agent, or Firm—Fulbright & JaWorski LLP.
(57)
ABSTRACT
The invention is directed to novel methods for the suppres

sion of photocarcinogenesis and photoimmunosuppression
in mice. The novel methods comprises the step of admin
istering to a subject a pharmaceutical composition compris
ing niacin and a pharmaceutical carrier.

10 Claims, 3 Drawing Sheets

U.S. Patent

inTcudmeor

Dec. 17, 2002

Sheet 1 of3

US 6,495,537 B1

40

2O

O

15

W

J

+

A

2O

'

A

'

25

Weeks after first UV treatment

FIG. 1A

—u— +uv +01% nic

+U\/ +05% nic
0-6-

Tumpoesr

+uv +1% nic

—

0.4

Weeks after first UV treatment

FIG. 1B

U.S. Patent

Dec. 17, 2002

Sheet 2 of3

US 6,495,537 B1

120

100_

A58.Um

-El— +UV +01% nic

80

v

6

B@ENi.

O

15

25

Days after tum0r challenge

FIG. 2

U.S. Patent

Dec. 17, 2002

Sheet 3 of3

r2:0.875
3

ft?)

US 6,495,537 B1

Dorsal Skin

...

..

_

_

—

—

E

T:

E

2

8
C
_

_

9

i1
D

<

1

—

—

Z

—

i

O

|

0.001

U
.

llllllli

0.01

|

UV-treated
Untreated _

llllllll

|

0.1

G'

l|ll1ll|

1

0/0 Diatary Niacin

r2:0.955

Ventral Skin

3 -

t

~

O
$0

_

._

—

—

E
_o
E

2

8
C
_

_

E

8
Q

<

1

'

—

Z

UV-treated
_
O

0.001

El
lilllllli

0.01

lllllllli

0.1

% Diatary Niacin

Untreated
1ll1|l|||

1

G

B
' 3

US 6,495,537 B1
1

2
The photoimmunusuppression and photocarcinogenesis

METHOD FOR INHIBITION OF
PHOTOCARCINOGENESIS OR
PHOTOIMMUNOSUPPRESSION USING
NIACIN

referred to in this application may be caused by natural or
arti?cial means. Natural means include direct or re?ected

sunlight. Arti?cial means include all man made ultraviolet

light sources such as UV lamps, residue UV from lighting
?xtures, and ultraviolet light emitted from industrial pro

CROSS REFERENCE TO RELATED
APPLICATIONS

This application claims bene?t of provisional patent
application Ser. No. 60/110,483 ?led Dec. 1, 1998. The
entire disclosure of provisional patent application Ser. No.

cesses and methods of manufacture.

DESCRIPTION OF THE DRAWINGS
10

60/110,483 is hereby incorporated by reference.

1.0% niacin throughout the study and (B) tumor multiplicity

BACKGROUND

1. Field of the Invention
This invention is directed to methods and compositions
for the oral administration of niacin for the prevention of

in UV-irradiated mice treated With niacin supplementation.
15

FIG. 2. depicts groWth of UVM12 tumor cells in naive

2. Description of the Background
Nonmelanoma skin cancers are the most frequent of

Values are means +/—SEM.

syngeneic mice after injection of splenocytes from

photocarcinogenesis and photoimmunosuppression.
human cancers, approximating 62.5% of the expected inci

FIG. 1 depicts (A) the rate of tumor development in
UVB/A irradiated mice treated With a diet of 0, 0.1, 0.5 or

20

UV-irradiated donors treated With niacin supplementation.
FIG. 3. depicts NAD content in dorsal (A) and ventral (B)
skin of niacin-supplemented mice. Closed circles represent
the average skin NAD, relative to protein, of mice that Were
treated With UV radiation, and an open square represents the

dence for all non-skin cancers combined (Parker, S L et al.,

CA Cancer J Clin 47, 5—27, 1997). Nonmelanoma skin

average skin NAD, relative to protein, of unsupplemented

cancers have been increasing in incidence at an annual rate

and untreated mice. Best-?t, logarithmic curves are shoWn
for both skin locations; error bars represent standard error.

of 3—6% (Gallagher, R P et al., J Am Acad Dermatol 23,
413—421, 1990). The increase in nonmelanoma skin cancer

25

rate is likely due to an increase in lifetime exposure to UV

DESCRIPTION OF THE INVENTION

radiation caused by a longer life expectancy and oZone

depletion (Moseley, H, and Mackie, R M, BritJ Dermatol
137, 101—103, 1997). Nonmelanoma skin cancers represent

As discussed above, ultraviolet irradiation can cause
30

considerable morbidity (Johnson M L et al., J Am Acad
Dermatol 11: 930—936, 1984). Both squamous cell carci

esis and photoimmunosuppression involve the use of sun

noma and basal cell carcinoma can be invasive and tend to
present as multiple primary tumors on visible areas of the

body (KWa, R E, et al.,JAmAcaa' Dermatol 26, 1—26, 1992;
Miller, S J, JAm Acad Dermatol 24, 1—13, 1991; Miller, S
J,JAmAcad Dermatol 24, 161—175, 1991; Schreiber, M M,
J Am Acad Dermatol 23, 1114—1118, 1990). The use of
sunscreens alone may not be suf?cient protection against
skin cancer development (Naylor, M F et al.,Arch Dermatol
131, 170—175, 1995). These observations indicate an
increasing need for novel skin cancer prevention strategies.

photocarcinogenesis and photoimmunosuppression in
humans. Current methods of preventing photocarcinogen

35

blocks. Sunblock (i.e., sunscreen) refers to any chemical that
When applied to the skin, reduces the amount of UV light
that reaches the skin. By preventing UV absorptions, sun
blocks can prevent photocarcinogenesis and photoimmuno
suppression. Sunblocks Were originally designed to prevent
sunburn (also knoWn as erythema), an acute reaction to
overexposure to the sun. The strength of sunblocks is

40

measured by the SPF index (Sun Protection Factor). An SPF
value of 15, for example, Will provide 15 times the protec
tion of bare skin to sunburns. HoWever, sunblocks are

disadvantageous because they require frequent application

SUMMARY OF THE INVENTION

to the skin. Further, every major class of sunblock has been

It is an object of the invention to suppress or reverse 45 linked to skin allergies.

To overcome the disadvantages of the current methods,
experiments Were performed to determine if niacin, admin
istered orally, can decrease photoimmunosuppression and

photoimmunosuppression and photocarcinogenesis in a sub

ject.
One embodiment of the invention is directed to a method

photocarcinogenesis.

for reducing photocarcinogenesis or photoimmunosuppres
sion in a subject. In the method, one or more oral adminis

50

tration of a pharmaceutical composition is given to the

One embodiment of the invention is directed to a method

for reducing photocarcinogenesis or photoimmunosuppres

subject. The pharmaceutical composition comprises niacin

sion in a subject. The subject can be any animal, such as a

in an amount effective to reduce photocarcinogenesis or

mammal. Preferably, the mammal is a human. In the method,
a pharmaceutical composition comprising niacin in an
amount effective to reduce photocarcinogenesis or photo

photoimmunosuppression. The pharmaceutical composition
may optionally comprise a pharmaceutically acceptable car
rier. The method may be used to reduce, eliminate, prevent

55

tocarcinogenesis or photoimmunosuppression.
In a preferred embodiment, the administration comprises

suppression.
The subject to be treated may be any animal. Thus, the
subject may be a mammal, such as, for example, a human.
The pharmaceutical composition may contain niacin in an
amount such that the dosage to be administered orally is

60

oral dosages of about 1 mg to about 100 mg per kilogram of

subject Weight. Preferably, the oral dosage is betWeen about
10 mg to about 40 mg per kilogram of subject Weight.
The niacin may be administered With a pharmaceutically

acceptable carrier. The pharmaceutically acceptable carrier

betWeen 1 mg niacin per kilogram of subject Weight to about

100 mg per kilogram of subject Weight. Preferably, the
dosage is betWeen 10 mg niacin per kilogram of subject
Weight to about 40 mg per kilogram of subject Weight.

immunosuppression is administered orally to the subject.
The method can reduce, eliminate, prevent or reverse pho

or reverse photocarcinogenesis. Further, the method may be
used to reduce, eliminate, prevent or reverse photoimmuno

65

may be any carrier knoWn in the ?eld as suitable for

pharmaceutical oral application. Suitable pharmaceutical
carriers and formulations are described, for example, in

US 6,495,537 B1
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4

Remington’s Pharmaceutical Sciences (19th ed.) (Genarro,
ed. (1995) Mack Publishing Co., Easton, Pa.).

The total UVB radiation dose Was approximately 1.41><106

Jm‘2 in the carcinogenesis experiments, and about 0.705><
105 Jm'2 in the passive transfer experiments, as measured

In addition, niacin and the pharmaceutically acceptable

With a UVX Digital Radiometer With a UVX-31 sensor

carrier may be enclosed in a hard or soft shell gelatin

(Ultraviolet Products, San Gabriel, Calif.).

capsule, compressed into tablets, or incorporated directly
into the individual’s diet. Speci?cally, niacin may be incor

EXAMPLE 3

porated With excipients and used in the form of ingestible

Passive Transfer Assay
The passive transfer assay determines photoimmunosup
pression by measuring the capacity of a mouse to reject
antigenic, syngeneic tumors. This assay has been described

tablets, buccal tablets, troches, capsules, elixirs,
suspensions, syrups, Wafers, and the like. When niacin is
administered orally, it may be mixed With other food forms
and pharmaceutically acceptable ?avor enhancers. When the
niacin agent is administered enterally, they may be intro
duced in a solid, semi-solid, suspension, or emulsion form
and may be compounded With any number of Well-knoWn,

10

previously (Gensler, H L, Nutr Cancer 29, 157—162, 1997;
Gensler, H L,] Cancer Res Clin Oncol 117, 345—350, 1991;

Gensler, H L, Nutr Cancer 22, 121—130, 1994). Brie?y,
spleens Were excised under aseptic conditions from mice

The light may be, for example, from natural sources such as

after 11 Weeks of UVB treatment. A total of 15 mice per
group Was used for analysis. The groups consist of (1) the
0% niacin diet group, (2) the 0.1% niacin diet group, (3) the
0.5% niacin diet group, and (4) the 1.0% niacin diet group.
Spleen cells isolated from the spleens Were triturated With
RPMI 1640 medium Without fetal bovine serum, Washed,
and resuspended in fresh medium. Splenocytes Were
injected into the lateral tail veins of 15 naive mice per
treatment group. Within 24 hours, recipients Were chal

sunlight or from manmade sources such as a broad spectrum
light source, a narroWband UV source, UVA source, UVB

lenged With about 5><105 UVM12 (syngeneic antigenic
UV-induced) tumor cells injected intradermally into the

pharmaceutically acceptable additives. Sustained release
oral delivery systems and/or enteric coatings for orally

15

administered dosage forms are knoWn in the art and also

contemplated.
It is understood that the photocarcinogenesis or photoim
munosuppression referred to in this application may refer to

20

any carcinogenesis or immunosuppression caused by light.

source, or UVC source.

25

set forth, in part, in the description Which folloWs and, in
part, Will be obvious from this description and understood by
the skilled artisan practicing this invention.

EXAMPLE 4

Tissue Extraction and Assay
30

EXAMPLE 1
Administration of Niacin

Six-Week-old speci?c-pathogen-free female BALB/
35

from tWo Weeks before treatment. Animals Were housed in
microisolators under barrier conditions With a 12:12-hour

light-dark cycle at 20+/—2° C. (SD).
Groups of 25 mice each received the basal diet Which
consisted of the American Institute of Nutrition 76A rodent
diet containing 10% corn oil and 30 mg niacin per kilogram

40

45

Were calculated from the diet consumed. Animals Were

supplied With steriliZed Water ad libitum.
50

EXAMPLE 2

chloric acid addition Was less than ?ve minutes. Samples
Were placed on ice for at least 10 min and centrifuged at 4°
C. for 10 min at 3000 rpm. Each supernatant Was collected

and neutraliZed With 1 M KOH/0.33 M K2HPO4. The
supernatants Were assayed for NAD; the precipitates Were
dissolved in 1 M NaOH for protein measurement. All
reagents for these assays Were purchased from Sigma, St.

Louis, Mo.
NAD content Was assessed as described previously

UV Irradiation
The mice Were exposed to UV radiation after three Weeks
of oral niacin administration. The animals Were shaved

(Jacobson, E L, and Jacobson, M K Meth Enzymol 280,
221—230, 1997; Jacobson, E L et al., J Cell Physiol 99,
55

food, and Water bottles Were removed from the microisola
tors While mice Were exposed to UV radiation emitted by

banks of six FS40 Westinghouse ?uorescent sun lamps for
30 min per day, ?ve days per Week. This UV regimen
continued for 22 Weeks in the carcinogenesis experiments,
and for 11 Weeks in the passive transfer assay experiments.
The cages Were systemically rotated during the study to
compensate for any differences in ?ux at different positions
under the lamps. The FS40 lamps emit a continuous spec

Jacobson, M KMeth Enzymol 280, 221—230, 1997). Finally,
protein in the sample. Total time from dissolving to per

treatments began, and throughout the study. Niacin intakes

dorsally With animal clippers each Week. The ?lter tops,

liquid nitrogen by mortar and pestle. The poWder Was then
transferred to a 15 ml centrifuge tube containing 1 ml of 1
M NaOH. This mixture Was rapidly neutraliZed With 0.27 ml
of 2 M H3PO4, so that total time in alkali Was less than 2
min. Next, 0.13 ml of 2 M phenaZine ethosulfate Was added
to convert NADH to the oxidiZed state (Jacobson, E L, and

1.4 ml of 1M HClO4 Was added to precipitate the total

diet, supplemented With 0, 0.1, 0.5, or 1.0% niacin (Dyets
Inc. Bethlehem, Pa.). All diets Were pelleted (Dyets Inc.)
Without heat or steam and stored under refrigeration for less
than 10 Weeks. Animals Were fed ad libitum and given fresh
diet three times per Week for three Weeks before UV

Dorsal and ventral skin samples Were excised from mice

at 29.5 Weeks after niacin supplementation began. Samples
Were immediately froZen in liquid nitrogen and stored at
—80° C. For nicotinamnide-adenine-dinucleotide (NAD) and
protein analyses, the tissue Was ground to a ?ne poWder in

cAnNTacfBR (H-2d) mice Were purchased from Taconic

Laboratory Animals (GermantoWn, NY.) and quarantined

?anks. Tumor groWth Was measured tWice Weekly With

vernier calipers.

Other embodiments and advantages of the invention are

60

417—426, 1979). The NAD assay is based on the principle of
enZymatic cycling betWeen oxidiZed and reduced states, in
Which NAD is rate-limiting for a series of ampli?cation
reactions. Control groups, Which received no supplemental
niacin, consisted of six mice each, Were compared With nine
or ten mice from the groups Which received niacin supple
mented diets. The Bradford method (Bradford, M M,Anal

Biochem 72, 248—254, 1976) Was employed to determine

protein concentration.
EXAMPLE 5

trum from 270 to 390 nm With peak emission at 313 nm. 65

Statistical Analysis

About 75% of the energy output is in the Wavelength range

Differences in primary tumor incidence betWeen the
experimental groups Were analyZed by the Wilcoxon rank

of 280—340 nm With about 23% in the 340—390 nm range.

US 6,495,537 B1
6

5
sum test. Analysis of the variance of the data Was performed
on the passive transfer results to test for a niacin treatment

TABLE I

effect on the tumor challenge growth rate. Dunnett’s test of
multiple comparisons Was then used to determine Which
treatment groups signi?cantly differed in the rate of tumor
groWth. For the NAD assay, the Q test Was ?rst applied to
the data to determine Whether questionable values should be
rejected. This test Was conducted at the 95% con?dence
level. The data Were then analyZed using the MIXED

procedure in the statistical analysis program SAS 6.11. The
MIXED procedure ?ts a variety of mixed linear models to

Niacin Consumption
Food

Treatment
+UV
10 +UV

+UV

standard linear model, With the generaliZation being that the

differences and variability in duplicate or triplicate samples
from the same mouse before the differences betWeen each

Niacin Ingested

Niacin
(g/kg diet)

(mg/mouse/
day)

Body Weight
(grams)

2.86 (0.55)
2.47 (0.54)

0.03
1.03

0.09 (0.02)
2.54 (0.56)

18.2 (0.54)
18.2 (0.77)

2.77 (0.66)

5.03

13.93 (3.3)

18.07 (1.37)

2.88 (0.60)

10.03

28.89 (6.0)

18.55 (0.91)

+05%
Niacin
15 +UV
+1%
Niacin

mouse in each group Was compared. This procedure result
ing in more precise group means than if each single value

carried equal Weight. Least-squares means for each group
Were calculated, and a multiple comparison betWeen these
means Was made after applying a Tukey-Kramer adjustment

Dietary

(g/mouse/
day)

+0.1%
Niacin

data, and a mixed linear model is a generaliZation of the
data are permitted to exhibit correlation and nonconstant
variability. In this manner, it Was possible to ?rst account for

Consumed

Values shoWn are means, standard deviations are shoWn in parentheses.
20

EXAMPLE 8

In?uence of Niacin Suplementation on Photoimmunosup

pression

for the p-values.

The reduced ability of UVB-irradiated mice to reject
EXAMPLE 6

syngeneic antigenic tumor cells is mediated by photoimmu
25

nosuppression. This response is measured by a passive

Reduction of Skin Tumor Development by Niacin Supple

transfer assay in Which splenocytes from a UV irradiated

mentation
Groups of 25 mice each Were fed the AIN76A rodent diet
containing 10% corn oil and 30 mg niacin per kilogram diet,

mouse are injected into a naive unirradiated mouse (Gensler,

H L and Magdaleno, M, Nutr Cancer 15, 97—106, 1991).
The accelerated groWth of tumor cells implanted in recipi
30

supplemented With 0, 0.1, 0.5, or 1.0% niacin. After three
Weeks of this diet, dorsally shaved mice Were exposed to UV
radiation for 30 min per day, ?ve days per Week for 22

transferred photoimmunosuppression. The capacity of nia

cin supplementation to prevent photoimmunosuppression

Weeks. This irradiation resulted in a cumulative exposure of

mice to approximately 1.41><106 Jm‘2 of UVB radiation.
Irradiated mice fed unsupplemented diets developed a 68%
skin tumor incidence by 26.5 Weeks after the ?rst UV

ents of splenocytes from UV irradiated donors as compared
With unirradiated donors is a measure of the amount of

Was measured in this experiment.
35

Brie?y, mice Were fed supplemented diets (0, 0.1%, 0.5 %,
or 1.0% niacin) for three Weeks before UV radiation treat
ments began. UVB irradiation consisted of ?ve 30 minute

exposure (FIG. 1A). Diet supplementation With 0.1, 0.5, or

exposures per Week for 11 Weeks. Splenic leukocytes (one

1.0% niacin reduced this incidence to 60, 48, or 28%,

organ equivalent) of UV irradiated mice Were injected
intravenously into each of 15 naive recipients. Within 24

respectively. This dose response yielded statistically signi?

40

cant reduction in mice fed the 1.0% and 0.5% niacin

hours, these mice Were challenged With an intradermal

supplemented diets (p=0.0257, Wilcoxon rank sum test).

injection of 5><105 UVM12 syngeneic antigenic tumor cells.

The results of the multiplicity of tumors are presented in
FIG. 1B. Supplementation of the basal diet With 0.1, 0.5, or

The groWth of these tumor cells Was measured and presented
in FIG. 2. The values displayed are the mean values +/—the

1.0% niacin reduced the number of tumors per mouse from

45 standard deviation. As can be seen from FIG. 2, the mean

0.72 to 0.6, 0.48, or 0.4%, respectively at 26.5 Weeks after

tumor siZe Was 21.9 sq mm in recipients of splenocytes from
unirradiated control mice, at 32 days after the tumor chal

the ?rst UV treatment.

lenge. Recipients of splenocytes from UVB-irradiated mice
EXAMPLE 7

50

Niacin Ingestion and Body Weights of UV-Irradiated Mice
Niacin ingestion Was calculated from diet consumption
recorded on 50% of the animals of each group. Unirradiated
mice fed the basal diet ingested an average of 0.09+/—0.03

mg niacin per day per mouse throughout the experiment, and

sis of variances indicates that there Was a signi?cant treat
ment effect on the tumor groWth rate (p=0.0001). Dunnett’s

test shoWs that the tumor challenge groWth in recipients of
55

UV irradiated mice had a similar food intake. As shoWn in

Table 1, UV irradiated mice fed the 0.1, 0.5, or 1.0% niacin

supplemented diets had average intakes of 2.54(+/—0.56),
13.93(+/—3.3), or 28.89(+/—6.0) mg niacin per day per
mouse, respectively throughout the study. These results

treated With 0, 0.1%, 0.5%, or 1.0% niacin supplementation
displayed mean tumor siZes of 91.6(+/—19.7), 79.8(+/—11.5),
41.9 (+/—11.7), or 13.2(+/—4.1) sq mm, respectively. Analy

60

splenocytes from UV irradiated mice treated With 0.5% or
1.0% niacin Was signi?cantly loWer than that in recipients of

splenocytes. This demonstrated that supplemental niacin in
the range of 0.5—1.0%, prevented UV-induced photoimmu
nosuppression as manifested by the ability of the recipient
mice to reject antigenic tumors.

demonstrate that there Was an increased amount of niacin

EXAMPLE 9

ingestion in mice fed higher concentrations of niacin in their
food. The body Weights of the UV-irradiated mice, With or

In?uence of Niacin Supplementation of Skin NAD Levels

Without supplemental niacin, Were similar (Table 1), sug
gesting that tumor prevention Was not in?uenced by other
nutritional factors.

UV exposure Was directed to the dorsal shaved skin of
65

treated mice. To assess the ability of ingested niacin to
enhance NAD levels in UV irradiated as Well as in unirra

diated skin, both unirradiated ventral skin and dorsal UV

US 6,495,537 B1
7

8

irradiated skin Were collected. For each mouse, either one,
tWo, or three skin samples Were collected at different sites

response to etoposide, a topoisomerase II inhibitor that

customarily results in increased p53 expression (Whitacre, C

form both the dorsal and ventral surfaces at 4.5 Weeks post

NAD, and these values Were expressed relative to protein

M et al., Cancer res 55: 3697—3701, 1995). This p53
doWn-regulation has also been demonstrated for human lung
?broblasts, skin ?broblasts, and mammary epithelial cells.

content to normaliZe the data.

P53 plays a critical role in skin squamous cell

UV treatment. The samples Were extracted to measure total

The results, shoWn in FIG. 3, shoW that niacin supple
mentation elevates cellular NAD. When the cellular NAD
levels Were plotted against the diet niacin level, it Was found
that the relationship of niacin concentration in the diet to
NAD in skin ?ts a logarithmic function. This logarithmic ?t
suggested that NAD content approaches saturation at

0.5—1.0% niacin supplementation. UV-irradiated mice
receiving 0.5 and 1.0% niacin supplementation had signi?
cantly higher skin NAD content than UV-irradiated mice
receiving no additional niacin (p<0.0001 for dorsal skin,
p=0.0114 for ventral skin, in 0.5% niacin supplemented
mice; and p=0.0025 for dorsal skin, p=0.0017 for ventral
skin, in 1.0% supplemented mice). The increase in NAD/
protein ratios appears greater for the ventral skin than the
dorsal skin in the 1.0% niacin group, although neither value
is signi?cantly different from values in the 0.5% niacin

carcinogenesis, as evidenced by the presence of p53 muta
tions in over 90% of human squamous cell carcinomas of the
10

p53 mutations are frequently an initiating step in cutaneous
squamous cell carcinoma (Ziegler, A et al., Nature 372,

773—776, 1994). The p53 protein is a transcription factor
15

Which has an increased protein half-life in murine kerati

20

genesis 15, 1089—1092, 1994). One of the doWnstream
genes activated by p53 in UVB/A irradiated keratinocytes is
the WAF1/CIP 1 gene (Liu, M and Pelling, J C Oncogene 10,
1955—1960, 1995). Its gene product, p21WAF1/CIP1, is a

nocytes exposed to UVB radiation (Liu, M et al., Carcino

cyclin dependent kinase inhibitor that causes a G1 cell-cycle

group. This suggests that a niacin concentration in the diet
of 0.5 to 1% approach cutaneous NAD saturation.

Oral niacin administration may prevent photoimmuno
suppression and photocarcinogenesis by a number of mecha
nisms. For example, oral niacin may modulate 1) ADP
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arrest by inhibiting the activity of the cyclin/cdK family
(Xiong, Y et al., Nature 366, 701—704, 1993). It has been
proposed that cell cycle arrest alloWs time for DNA repair
before DNA replication. The p53 protein binds to DNA
single strand scissions. PARP binds to the p53 protein as
Well as to DNA strand scissions in vivo, and the complex

ribose transfer reactions that are knoWn to affect base

excision repair, 2) p53 expression, Which is important in
nucleotide excision repair, and 3) apoptosis (Ménissier de

skin (Brash, D E, et al., Proc Natl Acad Sci, USA 88,
10124—10128, 1991). The occurrence of these mutations in
the early actinic keratotic stage of skin cancer suggests that
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retains its DNAbinding capacity (VaZiri, H et al., EMBO 16,
6018—6033, 1997; James, M R and Lehman, A R, Biochem
21, 4007—4013, 1982). Inhibition of PARP by 1,5

dihydroxyisoquinoline prevents p53 dependent induction of
P21Waf1/CIP1 in human myelogenous leukemia cells exposed
to y-radiation (VaZiri, H et al., EMBO 16, 6018—6033, 1997),

Murcia, J et al., Proc Natl Acad Sci, USA 94, 7303—7307;
1997; Ford, J M and HanaWalt, P C et al., JBiol Chem 272,

28073—28080, 1997; Ziegler, Aet al., Nature 372, 773—776,
1994.). Poly(ADP-ribose) polymerase is required in base

suggesting that PARP activity is required for activation of

excision repair, the pathWay for repair of oxidative DNA
damage, such as that induced by the UVA (320—400 nm)
portion of UV radiation (Ménissier de Murcia, J et al., Proc
Natl Acad Sci, USA 94, 7303—7307; Demple, B and
Harrison, L, Annu Rev Biochem 63, 915—948, 1994; Kvam,
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E and Tyrrell, R M, Carcinogenesis 18, 2379—2348, 1997).
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P21Waf1/CIP1 transcription by p53 protein. De?ciency of p53
is knoWn to result in reduced nucleotide excision repair of

UV-induced cyclobutane pyrimidine dimers and 6-4 photo
products in total genomic DNA of human ?broblasts and in
increased UV mutagenesis in murine ?broblasts (Ford, J M
and HanaWalt, P C et al., J Biol Chem 272, 28073—28080,

Expression of p53 is necessary for ef?cient nucleotide
excision repair of cyclobutane pyrimidine dimers and 6-4

1997; Yuan, J et al., Carcinogenesis 16, 2295—2300, 1995).
Cyclobutane pyrimidine dimers and 6-4 pyrimidine photo

photoproducts from DNA damaged by the UVC (200—280
nm) and UVB (280—320 nm) Wavelengths of UV radiation

products are produced in the DNA of cells exposed to UVB

(Ford, J M and HanaWalt, P C et al., J Biol Chem 272,

radiation (Rosentstein, B S, and Mitchell, D L, Photochem
45

p53 in mouse skin reduces the appearance of apoptotic

28073—28080, 1997; Rosentstein, B S, and Mitchell, D L,
Photochem Photobiol 45, 775—780, 1987). NAD, the major

keratinocytes generated by UVB irradiation (Ziegler, A et
al., Nature 372, 773—776, 1994). The apoptotic killing of
cells containing extensive UV-induced DNA damage is

metabolite of niacin, is a substrate for PARP, a nuclear

enZyme Which binds to, and is activated by DNA strand

scissions (James, M R and Lehman, A R, Biochem 21,
4007—4013, 1982). PARP interacts With numerous proteins

Photobiol 45, 775—780, 1987). Additionally, inactivation of
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thought to remove precancerous cells from the skin. These

activities of p53 suggest that doWn-regulation of the p53

involved in DNA repair, including XRCCI, DNA ligase III,
and p53 (Masson, M et al., Mol Cell Biol 18, 3563—3571,
1998; VaZiri, H et al., EMBO 16, 6018—6033, 1997). PARP

response to UV irradiation by NAD de?ciency could lead to

reduced induction of p21mf1/CIP1, decreased cell cycle
arrest, decreased nucleotide excision repair, increased

al., J Nutr 123: 1349—1355, 1993). The experiments dem

mutagenesis, and decreased apoptosis of severely
UV-damaged cells, all resulting in enhanced photocarcino

onstrate that niacin ingestion can determine NAD concen

genesis.

tration in the skin, as had been previously reported in a
number of human tissues (Canner, P H et al., J Am Coll

repair of oxidative DNA damage induced by sunlight. The

activity can be limited by NAD concentration (Zhang, J Z et

Cardio 8, 1245—1255, 1986; Demple, B and Harrison, L,
Annu Rev Biochem 63, 915—948, 1994). Exposure of normal
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As a substrate for PARP, decreased NAD may in?uence
60

E and Tyrrell, R M, Carcinogenesis 18, 2379—2348, 1997).
Many DNAbase damages generated by oxidative processes,

human ?broblasts to UV radiation results in activation of

PARP and concomitant utiliZation of NAD (Gensler, H L, J
Cancer Res Clin Oncol 117, 345—350, 1991; Jacobson, E L
et al., J Biol Chem 258, 103—107, 1983). Chinese hamster
lung ?broblast cells With reduced NAD content display
doWn-regulation of p53 levels and inability to mount a p53

longer UV Wavelengths, above 334 nm and near visible

radiations, cause extensive oxidative DNA damage (Kvam,
ioniZing radiation, or by simple alkylating agents are cor
65

rected by base excision repair (Klungland, A and Lindahl, T,
EMBO 16, 3341—3348, 1997; Seeberg, E et al., Trends
Biochem Sci 20, 391—397, 1995; Demple, B and Harrison, L,

US 6,495,537 B1
9
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We claim:

Annu Rev Biochem 63, 915—948, 1994). PARP has been
implicated in the base excision repair pathway in vivo since
PARP knockout mice are highly sensitive to alkylating

1. A method for inhibiting photocarcinogenesis or photo
immunosuppression in a subject comprising administering a

agents and to y-radiation (Ménissier de Murcia, J et al., Proc
Natl Acad Sci, USA 94, 7303—7307, 1997). By binding to

pharmaceutical composition consisting essentially of niacin
to a subject in need thereof Wherein said niacin is in an
amount effective to inhibit photocarcinogenesis or photoim

DNA strand scissions and to base excision repair proteins

XRCC1, DNA polymerase [3, and DNA ligase III, PARP
detects DNA strand breaks and is thought to recruit proteins
to form a multiprotein repair complex to process the strand
scissions (Masson, M et al., Mol Cell Biol 18, 3563—3571,

munosuppression in said subject.
10

1998). Niacin supplementation may also protect against
oxidative DNA damage by acting as an antioxidant (Kamat,
J P and Devasagayam, T P, Chem Biol Interact 99, 1—16,

1996).
In summary, our results demonstrate that niacin supple
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mentation inhibits photocarcinogenesis and photoimmuno
suppression in mice. Furthermore, ingestion of niacin leads

2. The method of claim 1, Wherein said subject is a
mammal.
3. The method of claim 2 Wherein said mammal is a
human.
4. The method of claim 1, Wherein said administration

comprises betWeen about 1 mg niacin per kilogram of
subject Weight to about 100 mg per kilogram of subject

Weight.

to increased levels of NAD in skin. This increase Was

5. The method of claim 1, Wherein said administration
comprises betWeen about 10 mg niacin per kilogram of

evident even in skin Which had been repeatedly exposed to
UV radiation (an agent knoWn to enhance NAD

Weight.

subject Weight and about 40 mg per kilogram of subject

consumption). These results suggest that prevention of skin
carcinogenesis by supplemental niacin results from block
age of both UV-induced photoimmunosuppression and of
cutaneous NAD depletion. Maintenance of NAD levels in
skin With consequent PARP enhancement of base excision
repair or UV induced oxidative DNA damage likely con
tributes to the skin cancer prevention capacity of supple
mental niacin.
Other embodiments and uses of the invention Will be
apparent to those skilled in the art from consideration of the

6. The method of claim 1, Wherein said photocarcinogen
esis or photoimmunosuppression is by sunlight or ultraviolet
radiation.
7. The method of claim 1, Wherein said pharmaceutical
25

able carrier.
8. The method of claim 1 Wherein said pharmaceutical

composition comprising niacin is administered orally to said

subject.
9. The method of claim 1, Wherein the subject Will be
exposed to a photocarcinogenic agent.
10. The method of claim 1, Wherein the subject Will be
exposed to a photoimmunosuppresive agent.

speci?cation and practice of the invention disclosed herein.
All US. patents and applications and other references noted

herein are speci?cally incorporated by reference. The speci
?cation and examples should be considered exemplary only
With the true scope and spirit of the invention indicated by

the folloWing claims.

composition further comprises a pharmaceutically accept
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